Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: MRNA

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

55 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin
Today, 4:28 AM
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday.

ALXO

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Moderna Scraps mRNA-Based Antibody Program Targeting Chikungunya Virus

By Vandana Singh
Today, 4:28 AM
Moderna Inc (NASDAQ:MRNA) has quietly announced the discontinuation of an mRNA program for the chikungunya virus. The Company is scrapping Phase…

MRNA

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Small Cap

Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook

By Lisa Levin
Today, 4:28 AM
Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39.

ETSY

Read More
1 minute read
  • News

From Moderna Earnings Conference Call: Co. Is Working Through Delivery Challenges, Supply Chain Became More Complex

By Benzinga Newsdesk
Today, 4:28 AM
-Reuters

MRNA

Read More
1 minute read
  • Markets
  • Movers
  • Pre-Market Outlook

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights
Today, 4:28 AM
 

ARTL

Read More
1 minute read
  • Earnings
  • News

Moderna Q3 EPS $7.70 Misses $9.09 Estimate, Sales $5.00B Miss $6.23B Estimate

By Benzinga Newsdesk
Today, 4:28 AM
Moderna (NASDAQ:MRNA) reported quarterly earnings of $7.70 per share which missed the analyst consensus estimate of $9.09 by 15.29 percent. This is a 1405.08 percent increase over losses of $(0.59) per share from the

MRNA

Read More
1 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook
  • Trading Ideas

5 Stocks To Watch For November 4, 2021

By Lisa Levin
Today, 4:28 AM
Some of the stocks that may grab investor focus today are: Wall Street expects Moderna, Inc. (NASDAQ: MRNA) to report quarterly earnings at $8.95 per share on revenue of $6.45 billion before the opening bell. Moderna shares rose 0.1% to $346.00 in pre-market trading.

ABNB

Read More
32 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 4, 2021

By Benzinga Insights
Today, 4:28 AM
  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

Read More
1 minute read
  • FDA
  • News

ModernaTX Sponsored Study Titled ‘A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting

By Benzinga Newsdesk
Today, 4:28 AM
https://clinicaltrials.gov/ct2/show/NCT05105048

MRNA

Read More
2 minute read
  • Markets
  • Options

Moderna Whale Trades Spotted

By Benzinga Insights
Today, 4:28 AM
A whale with a lot of money to spend (and possibly insider knowledge) has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 49 strange trades.

MRNA

Posts navigation

Previous 1 … 74 75 76 … 136 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service